Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

A Engelman

Showing results (161-170 of 238) with videos related to

Pageof 24
Sort By:
Science (New York, N.Y.)|April 28, 2007
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingJeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.
Science Translational Medicine|August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanomaRyan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancerLecia V Sequist, Scott Gettinger, Neil N Senzer, et al.
Ebiomedicine|February 13, 2016
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung CancerRyohei Katayama, Takuya Sakashita, Noriko Yanagitani, et al.
Science Translational Medicine|August 2, 2013
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancerMoshe Elkabets, Sadhna Vora, Dejan Juric, et al.
Cancer Research|December 20, 2007
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibJeffrey A Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2012
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastasesDavid P Kodack, Euiheon Chung, Hiroshi Yamashita, et al.
Cancer Cell|February 5, 2010
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLCAlexa B Turke, Kreshnik Zejnullahu, Yi-Long Wu, et al.
Cell Reports|March 24, 2023
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitorsRalph Tiedt, Frederick J King, Christelle Stamm, et al.
Nature Medicine|November 26, 2008
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersJeffrey A Engelman, Liang Chen, Xiaohong Tan, et al.
Pageof 24

Showing results (161-170 of 238) with videos related to

Sort By:
Pageof 24
Science (New York, N.Y.)|April 28, 2007
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signalingJeffrey A Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi, et al.
Science Translational Medicine|August 2, 2013
TORC1 suppression predicts responsiveness to RAF and MEK inhibition in BRAF-mutant melanomaRyan B Corcoran, Stephen Michael Rothenberg, Aaron N Hata, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 14, 2010
Activity of IPI-504, a novel heat-shock protein 90 inhibitor, in patients with molecularly defined non-small-cell lung cancerLecia V Sequist, Scott Gettinger, Neil N Senzer, et al.
Ebiomedicine|February 13, 2016
P-glycoprotein Mediates Ceritinib Resistance in Anaplastic Lymphoma Kinase-rearranged Non-small Cell Lung CancerRyohei Katayama, Takuya Sakashita, Noriko Yanagitani, et al.
Science Translational Medicine|August 2, 2013
mTORC1 inhibition is required for sensitivity to PI3K p110α inhibitors in PIK3CA-mutant breast cancerMoshe Elkabets, Sadhna Vora, Dejan Juric, et al.
Cancer Research|December 20, 2007
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinibJeffrey A Engelman, Kreshnik Zejnullahu, Christopher-Michael Gale, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 17, 2012
Combined targeting of HER2 and VEGFR2 for effective treatment of HER2-amplified breast cancer brain metastasesDavid P Kodack, Euiheon Chung, Hiroshi Yamashita, et al.
Cancer Cell|February 5, 2010
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLCAlexa B Turke, Kreshnik Zejnullahu, Yi-Long Wu, et al.
Cell Reports|March 24, 2023
Integrated CRISPR screening and drug profiling identifies combination opportunities for EGFR, ALK, and BRAF/MEK inhibitorsRalph Tiedt, Frederick J King, Christelle Stamm, et al.
Nature Medicine|November 26, 2008
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancersJeffrey A Engelman, Liang Chen, Xiaohong Tan, et al.
Pageof 24